Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges.
On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening.

BMI \<23 kg/m² at screening
History of type 1 diabetes mellitus
HbA1c ≥10% (86 mmol/mol) at screening
Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness
Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening
Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
History/family history (first degree) of medullary thyroid cancer or MEN2

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.